A Randomized Phase III Trial of Dose Dense Weekly Paclitaxel Combined With Carboplatin Versus Dose Dense Weekly Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921), Combined With Carboplatin Versus Every-3-Weeks Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921) Combined With Carboplatin in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Trial Profile

A Randomized Phase III Trial of Dose Dense Weekly Paclitaxel Combined With Carboplatin Versus Dose Dense Weekly Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921), Combined With Carboplatin Versus Every-3-Weeks Paclitaxel Plus Bevacizumab (NSC #704865, IND #7921) Combined With Carboplatin in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2018

At a glance

  • Drugs Paclitaxel (Primary) ; Bevacizumab; Carboplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 28 Dec 2017 Planned End Date changed from 1 Dec 2014 to 6 Jun 2027.
    • 07 Feb 2017 Results (n=70) of ACRIN 6695 study assessing association between CTP biomarkers and PFS-6, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 25 Feb 2016 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top